- Home
- MDRR vs QNRX Comparison
MDRR vs QNRX Comparison
Compare MDRR & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDRR | QNRX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 14.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MDRR | QNRX |
|---|---|---|
| Price | $11.56 | $7.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.1K | ★ 13.7K |
| Earning Date | 11-06-2025 | 03-10-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $0.21 |
| 52 Week High | $14.52 | $41.80 |
Technical Indicators
Market Signals| Indicator | MDRR | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 41.75 |
| Support Level | $11.48 | $6.85 |
| Resistance Level | $12.49 | $9.93 |
| Average True Range (ATR) | 0.33 | 0.41 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 41.08 | 36.92 |
Price Performance
Historical ComparisonAbout MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.